全文获取类型
收费全文 | 12485篇 |
免费 | 1160篇 |
国内免费 | 15篇 |
学科分类
医药卫生 | 13660篇 |
出版年
2021年 | 253篇 |
2020年 | 158篇 |
2019年 | 250篇 |
2018年 | 259篇 |
2017年 | 196篇 |
2016年 | 208篇 |
2015年 | 246篇 |
2014年 | 335篇 |
2013年 | 494篇 |
2012年 | 801篇 |
2011年 | 753篇 |
2010年 | 416篇 |
2009年 | 380篇 |
2008年 | 640篇 |
2007年 | 618篇 |
2006年 | 640篇 |
2005年 | 629篇 |
2004年 | 607篇 |
2003年 | 503篇 |
2002年 | 543篇 |
2001年 | 321篇 |
2000年 | 265篇 |
1999年 | 239篇 |
1998年 | 125篇 |
1997年 | 105篇 |
1996年 | 105篇 |
1995年 | 110篇 |
1994年 | 91篇 |
1993年 | 73篇 |
1992年 | 232篇 |
1991年 | 203篇 |
1990年 | 201篇 |
1989年 | 217篇 |
1988年 | 195篇 |
1987年 | 172篇 |
1986年 | 164篇 |
1985年 | 174篇 |
1984年 | 146篇 |
1983年 | 131篇 |
1982年 | 81篇 |
1981年 | 66篇 |
1980年 | 71篇 |
1979年 | 117篇 |
1978年 | 92篇 |
1977年 | 89篇 |
1975年 | 78篇 |
1974年 | 94篇 |
1973年 | 92篇 |
1972年 | 82篇 |
1970年 | 71篇 |
排序方式: 共有10000条查询结果,搜索用时 406 毫秒
1.
2.
Jasmine Poonian Nicola Walsham Thomas Kilner Elizabeth Bradbury Kristen Brooks Emma West 《Emergency medicine Australasia : EMA》2020,32(4):700-702
Emergency Medicine staff in Australia and New Zealand are at the forefront of the healthcare response to COVID‐19. This article describes a well‐being plan for ED staff that has been devised to mitigate against the negative psychological impact of the COVID‐19 pandemic. 相似文献
3.
4.
5.
6.
Katie Mycock Lin Zhan Gavin Taylor-Stokes Gary Milligan Debanjali Mitra 《Current oncology (Toronto, Ont.)》2021,28(1):678
Background: Palbociclib is a selective cyclin-dependent kinase (CDK) 4/6 inhibitor used in combination with aromatase inhibitors or fulvestrant for patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2 (HER2)-negative advanced/metastatic breast cancer (ABC/MBC). Palbociclib was the first CDK 4/6 inhibitor approved for HR+/HER2− ABC/MBC treatment in Canada in combination with letrozole (P+L) as an initial endocrine-based therapy (approved March 2016), or with fulvestrant (P+F) following disease progression after prior endocrine therapy (approved May 2017). The Ibrance Real World Insights (IRIS) study () collected real-world outcomes data for palbociclib-treated patients in several countries, including Canada. Methods: This retrospective chart review included women with HR+/HER2− ABC/MBC receiving P+L or P+F in Canada. Physicians reviewed medical records for up to 14 patients, abstracting demographic and clinical characteristics, treatment patterns, and clinical outcomes. Progression-free rates (PFRs) and survival rates (SRs) at 6, 12, 18, and 24 months were estimated via Kaplan–Meier analysis. Results: Thirty-three physicians examined medical records for 247 patients (P+L, n = 214; P+F, n = 33). Median follow-up was 8.8 months for P+L and 7.0 months for P+F. Most patients were initiated on palbociclib 125 mg/d (P+L, 90.2%; P+F, 84.8%). Doses were reduced in 16.6% of P+L and 14.3% of P+F patients initiating palbociclib at 125 mg/d. The PFR for P+L was 90.3% at 12 months and 78.2% at 18 months; corresponding SRs were 95.6% and 93.0%. For P+F, 6-month PFR was 91.0%; 12-month SR was 100.0%. Conclusions: Dose reduction rates were low and PFR and SR were high in this Canadian real-world assessment of P+L and P+F treatments, suggesting that palbociclib combinations are well tolerated and effective. NCT03159195相似文献
7.
Emarene Kalaw Malcolm Lim Jamie R. Kutasovic Anna Sokolova Lucinda Taege Kate Johnstone James Bennett Jodi M. Saunus Colleen Niland Kaltin Ferguson Irma Gresshoff Mark Bettington Nirmala Pathmanathan Gary M. Tse David Papadimos Rajadurai Pathmanathan Gavin Harris Rin Yamaguchi Puay Hoon Tan Stephen Fox Sandra A. O’Toole Peter T. Simpson Sunil R. Lakhani Amy E. McCart Reed 《British journal of cancer》2020,123(11):1665
8.
Fluid role boundaries: exploring the contribution of the advanced nurse practitioner to multi‐professional palliative care 下载免费PDF全文
9.
10.
Ann G Schwartz Geoffrey M Prysak Valerie Murphy Fulvio Lonardo Harvey Pass Jan Schwartz Sam Brooks 《Clinical cancer research》2005,11(20):7280-7287
PURPOSE: A role for estrogens in determining lung cancer risk and prognosis is suggested by reported sex differences in susceptibility and survival. Archival lung tissue was evaluated for the presence of nuclear estrogen receptor (ER)-alpha and ER-beta and the relationship between ER status, subject characteristics, and survival. EXPERIMENTAL DESIGN: Paraffin-embedded lung tumor samples were obtained from 214 women and 64 men from two population-based, case-control studies as were 10 normal lung autopsy samples from patients without cancer. Nuclear ER-alpha and ER-beta expression was determined by immunohistochemistry. Logistic regression was used to identify factors associated with ER positivity and Cox proportional hazards models were used to measure survival differences by ER status. RESULTS: Neither tumor (0 of 94) nor normal (0 of 10) lung tissue stained positive for ER-alpha. Nuclear ER-beta positivity was present in 61% of tumor tissue samples (170 of 278; 70.3% in men and 58.3% in women) and 20% of normal tissue samples (2 of 10; P = 0.01). In multivariate analyses, females were 46% less likely to have ER-beta-positive tumors than males (odds ratio, 0.54; 95% confidence interval, 0.27-1.08). This relationship was stronger and statistically significant in adenocarcinomas (odds ratio, 0.40; 95% confidence interval, 0.18-0.89). Women with ER-beta-positive tumors had a nonsignificant 73% (P = 0.1) increase in mortality, whereas men with ER-beta-positive tumors had a significant 55% (P = 0.04) reduction in mortality compared with those with ER-beta-negative tumors. CONCLUSIONS: This study suggests differential expression by sex and influence on survival in men of nuclear ER-beta in lung cancer, particularly in adenocarcinomas. 相似文献